• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

    10/24/23 3:56:02 PM ET
    $GMVD
    Medical/Dental Instruments
    Health Care
    Get the next $GMVD alert in real time by email
    SC 13D/A 1 ea187226-13da1rubini_gmed.htm AMENDMENT NO. 1 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D
    (Amendment No. 1)

     

    Under the Securities Exchange Act of 1934

     

    G Medical Innovations Holdings Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    G39462141
    (CUSIP Number)

     

    Jonathan B. Rubini

    P.O. Box 202845

    Anchorage, Alaska 99520-2845

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    September 29, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. G39462141 13D Page 2 of 5 Pages

     

    1.

    Names of reporting persons

     

    Jonathan B. Rubini

     
    2. Check the appropriate box if a member of group (See Instructions) (a) ☐
        (b) ☐
    3. SEC use only
       
    4.

    Source of funds (See Instructions)

     

    PF

    5. Check if disclosure of legal proceedings is required pursuant to item 2(d) or 2(e)

    ☐

     

    6.

    Citizenship or place of organization

     

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    7.

    Sole voting power

     

    7,823,152(1)

    8.  

    Shared voting power

     

    3,265(1)

    9.  

    Sole dispositive power

     

    7,823,152(1)

    10.  

    Shared dispositive power

     

    3,265(1)

    11.

    Aggregate amount beneficially owned by each reporting person

     

    7,826,417 (1)

    12. Check if the aggregate amount in row (11) excludes certain shares (See Instructions)

    ☐

     

    13.

    Percent of class represented by amount in row (11)

     

    23.3%(2)

    14.

    Type of reporting person (See Instructions)

     

    IN

     

    (1)See Item 5.
    (2)Based on 33,477,001 Ordinary Shares issued and outstanding as of October 23, 2023 as reported by the Issuer to the Reporting Person.

     

     

     

    CUSIP No. G39462141 13D Page 3 of 5 Pages

     

    This Amendment No. 1 to Schedule 13D (this “Amendment”) amends and supplements the Statement on Schedule 13D initially filed by Jonathan B. Rubini (the “Reporting Person”) with the Securities and Exchange Commission (the “SEC”) on February 3, 2023 (the “Statement”) with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of G Medical Innovations Holdings Ltd., a Cayman Islands exempted company (the “Issuer”).

     

    The following amends and supplements Items 3, 4, 5, 6 and 7 of the Statement.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    Item 3 of the Schedule 13D is hereby amended and supplemented to add the following:

     

    The Reporting Person purchased the Ordinary Shares described in Item 4 using his personal funds.

     

    Item 4. Purpose of Transaction

     

    Item 4 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

     

    On April 7, 2021, the Issuer obtained a convertible loan from the Reporting Person in an aggregate amount of $600,000, against issuance of convertible debentures (as amended on June 1, 2022, the “10% Convertible Debenture”) and warrants to purchase 3,907 Ordinary Shares (the “2021 Warrants”). The 2021 Warrants have an exercise price per share of $1.75 and are exercisable until April 7, 2026.

     

    On November 30, 2021, the Issuer entered into a joint development, licensing and distribution agreement with Heartbuds AK, LLC (“Heartbuds”), an Alaska limited liability company and an affiliate of the Reporting Person (the “Joint Development Agreement”). As contemplated in the Joint Development Agreement, Heartbuds received (i) 3,265 Ordinary shares, and (ii) $1,000,000 in options to acquire Ordinary Shares (the “Heartbuds Options”). In accordance with the terms of the Joint Development Agreement, subject to achievement of certain milestone, vesting and other terms and conditions set forth in the Joint Development Agreement, the Heartbuds Options will become exercisable into 13,106 Ordinary Shares.

      

    On October 20, 2022, the Issuer and the Reporting Person entered into a Securities Purchase Agreement (the “2022 SPA”) in connection with a private placement investment for 79,365 Ordinary Shares and warrants to purchase 79,366 Ordinary Shares with a price of $6.30 per share and associated warrant (the “2022 Warrant”) for aggregate consideration of $500,000. The 2022 Warrants have an exercise price per share of $6.30 and are exercisable at any time beginning 30 days after issuance with a term of five years from issuance. In connection with the 2022 SPA, the Reporting Person and the Issuer agreed, inter alia, to amend the applicable interest rate and conversion price adjustment date of the 10% Convertible Debenture.

     

    On April 18, 2023, the Issuer repaid in full the principal and accrued interest of the 10% Convertible Debentures.

     

    On September 29, 2023, the Issuer and the Reporting Person entered into a Securities Purchase Agreement (the “2023 SPA”) in connection with a private placement investment and issuance of a total of 9,009,009 Ordinary Shares (the “First Closing Shares”) with a price of $0.0555 per share for an aggregate consideration of $500,000 (the “First Closing”). Pursuant to the 2023 SPA, the Issuer will issue additional 9,009,009 Ordinary Shares (the “Second Closing Shares”) with a price of $0.0555 per share for an additional aggregate consideration of $500,000 subject to achievement of certain milestone (the “Milestone”) and other terms and conditions set forth in the 2023 SPA (the “Second Closing”) and, if the Milestone and Second Closing shall not occur until January 30, 2024 (the “Second Closing Deadline”), the Reporting Person may (but is not obligated) to purchase the Second Closing Shares by sending a notice to the Issuer within six months following the Second Closing Deadline. In connection with the 2023 SPA, the Issuer’s Chief Executive Officer (the “CEO”) made a commitment that he would remit to the Reporting Person a portion of any payments made to the CEO by the Issuer or any subsidiary that are in excess of a monthly base salary threshold (the “CEO Letter”). On or about October 15, 2023, the Reporting Person assigned a portion of his rights and obligations under the 2023 SPA and the CEO Letter to unaffiliated third parties, such that (i) at the First Closing, he will be issued 7,657,658 Ordinary Shares out of the First Closing Shares (the “2023 Shares”) and (ii) at the Second Closing, if any, he will be issued 7,657,658 Ordinary Shares out of the Second Closing Shares (the “2023 Milestone Shares”). The issuance of the 2023 Shares to the Reporting Person occurred on or about October 16, 2023.

     

     

     

    CUSIP No. G39462141 13D Page 4 of 5 Pages

     

    The Reporting Person intends to closely monitor his investments and may from time to time take advantage of opportunities presented to him. The Reporting Person may in the future also formulate plans or proposals regarding the Issuer, including possible future plans or proposals concerning events or transactions of the kind described in paragraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon the Reporting Person’s continuing review of his investments and various other factors, including those mentioned above, the Reporting Person may (subject to any applicable securities laws and lock-up arrangements) decide to purchase additional Ordinary Shares or to sell all or any part of the Ordinary Shares or other securities owned by him from time to time, on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable, although he has no current plans to do so. Except as set forth above, the Reporting Person has no present plans or proposals that relate to or would result in any of the actions required to be described in subsections (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5. Interest in Securities of the Issuer

     

    The aggregate percentage of shares reported beneficially owned by the Reporting Person is based on 33,477,001 Ordinary Shares issued and outstanding as of October 23, 2023 as reported by the Issuer to the Reporting Person.

     

    (a) The Reporting Person beneficially owns 7,826,417 Ordinary Shares of the Issuer, which constitute 23.3% of the outstanding Ordinary Shares of the Issuer. For the sake of clarity, such 7,826,417 Ordinary Shares (i) include the Ordinary Shares underlying the 2021 and 2022 Warrants and the Ordinary Shares held by Heartbuds and (ii) exclude the 2023 Milestone Shares and the Ordinary Shares underlying the Heartbuds Options.

     

    (b) The Reporting Person has sole voting and dispositive power of 7,823,152 Ordinary Shares of the Issuer. The Reporting Person, by virtue of its affiliation with Heartbuds, may be deemed to beneficially own, and share the power to vote and dispose, of the 3,265 Ordinary Shares held by Heartbuds.

     

    (c) Except as set forth herein, the Reporting Person has not effected any transactions in the Ordinary Shares in the 60 days preceding September 29, 2023.

     

    (d), (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    Other than as described herein (including Item 4 above), there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and any other person with respect to any securities of the Issuer (including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies).

     

    Item 7. Material to be Filed as Exhibits

     

    99.1 Form of 2021 Warrants (incorporated by reference to Exhibit 10.38 to the Issuer’s Form F-1/A filed with the SEC on April 22, 2021).
       
    99.2 2022 SPA (incorporated by reference to Exhibit 99.1 to the Issuer’s Form 6-K filed with the SEC on October 27, 2022).
       
    99.3 Form of 2022 Warrants (incorporated by reference to Exhibit 99.3 to the Issuer’s Form 6-K filed with the SEC on October 27, 2022).
       
    99.4 2023 SPA (incorporated by reference to Exhibit 99.1 to the Issuer’s Form 6-K filed with the SEC on October 10, 2023).
       
    99.5 Joint Development Agreement (incorporated by reference to Exhibit 10.39 to the Issuer’s Form F-1 filed with the SEC on January 31, 2022).

     

     

     

    CUSIP No. G39462141 13D Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: October 24, 2023

     

      By: /s/ Jonathan B. Rubini
        Jonathan B. Rubini

     

     

     

     

     

     

     

    Get the next $GMVD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GMVD

    DatePrice TargetRatingAnalyst
    1/18/2022$6.00Buy
    EF Hutton
    More analyst ratings

    $GMVD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • G Medical Innovations Will Provide Services to Veterans and Military Personnel by Partnering With Resilient Support Services

      Rehovot, Israel, Aug. 17, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations"), an industry innovator in comprehensive remote patient monitoring solutions, today announced that its wholly-owned subsidiary, G Medical Innovations USA, Inc., has entered into an agreement with Resilient Support Services Inc. ("RSS") to expand the health care and remote patient monitoring capabilities to U.S. veterans and military personnel. RSS is a Service-Disabled Veteran-Owned Business that partners with U.S. federal agencies and private sector businesses that are concerned with improving the medical care of veterans and the military community.  G Medi

      8/17/23 6:00:00 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • G Medical Innovations' CEO Issues Update to Shareholders, August 2023

      Rehovot, Israel, Aug. 07, 2023 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical Innovations" or the "Company"), a global leader in next-generation mobile health (mHealth) and digital health, today issued the following update to shareholders from President and CEO Dr. Yacov Geva. Dear Fellow Shareholders, We are proud to report that at this halfway point of 2023, G Medical has met several significant milestones and is on track to show revenue growth and gain profitability. Our Company has experienced growth in its monitoring services, and we are getting ready to add revenue with our "At Home Test Kits" business unit as we are no

      8/7/23 9:27:00 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification

      Rehovot, Israel, May 19, 2023 (GLOBE NEWSWIRE) --  G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company, announced today that on May 15, 2023 it received a written notice (the "Notice") from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.

      5/19/23 4:15:00 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Awm Investment Company, Inc.

      4 - G Medical Innovations Holdings Ltd. (0001760764) (Issuer)

      4/4/23 4:21:22 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form 3: New insider Awm Investment Company, Inc. claimed ownership of 1,437,500 shares

      3 - G Medical Innovations Holdings Ltd. (0001760764) (Issuer)

      4/4/23 4:10:17 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on G Medical Innovations with a new price target

      EF Hutton initiated coverage of G Medical Innovations with a rating of Buy and set a new price target of $6.00

      1/18/22 9:06:41 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

      SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

      2/7/24 1:12:01 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

      SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

      10/24/23 3:56:02 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by G Medical Innovations Holdings Ltd. (Amendment)

      SC 13D/A - G Medical Innovations Holdings Ltd. (0001760764) (Subject)

      8/25/23 4:15:27 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    SEC Filings

    See more
    • SEC Form 6-K filed by G Medical Innovations Holdings Ltd.

      6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

      12/18/23 4:39:15 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by G Medical Innovations Holdings Ltd.

      6-K - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

      11/29/23 9:27:53 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care
    • SEC Form D filed by G Medical Innovations Holdings Ltd.

      D - G Medical Innovations Holdings Ltd. (0001760764) (Filer)

      10/25/23 8:42:02 AM ET
      $GMVD
      Medical/Dental Instruments
      Health Care

    $GMVD
    Financials

    Live finance-specific insights

    See more
    • G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update

      Irvine, CA, Nov. 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) ("G Medical" or the "Company"), an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms, today announced its financial results and provided a business update for the six months ended June 30, 2022. First Half 2022 Financial Results During the six months period ended June 30, 2022, the Company performed over 100,000 tests which includes four types of diagnostic tests –Rapid Antigen, A/B Flu, PCR and Antibody; in connection with these tests, the Company expects to submit approximately

      11/18/22 5:15:00 PM ET
      $GMVD
      Medical/Dental Instruments
      Health Care